FrancophonIA/ELRC3.0 huggingface dataset:
English: Musculoskeletal and connective tissue disorders Common: Arthralgia, muscle disorders.
Estonian: Lihas-skeleti ja sidekoe kahjustused Sage: liigesevalu, lihashäired Harv: rabdomüolüüs
English: Check with your doctor or pharmacist if you are not sure.
Estonian: võtmist pidage nõu oma arsti või apteekriga.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet container - Lamivudine Teva Pharma B.V. 300mg film-coated tablets
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Tabletipurk - Lamivudine Teva Pharma B.V.
English: Lamivudine Teva Pharma B.V. can be used during pregnancy if clinically needed.
Estonian: Kui te olete raseduse ajal võtnud Lamivudine Teva Pharma B.V.
English: What Lamivudine Teva Pharma B.V. contains
Estonian: Mida Lamivudine Teva Pharma B.V.
English: Each infusion lasts 10 or 30 minutes, according to the dose.
Estonian: Iga infusioon kestab vastavalt annusele 10 või 30 minutit.
English: What measures are being taken to ensure the safe and effective use of Kyprolis?
Estonian: Mis meetmed võetakse, et tagada Kyprolise ohutu ja efektiivne kasutamine?
English: Kyprolis received a marketing authorisation valid throughout the EU on 19 November 2015.
Estonian: Kyprolis on saanud müügiloa, mis kehtib kogu ELis, 19. novembril 2015.
English: Other information about Kyprolis
Estonian: Muu teave Kyprolise kohta
English: It is given in four-week treatment cycles, on days 1, 2, 8, 9, 15 and 16 of each cycle.
Estonian: Seda manustatakse neljanädalaste ravitsüklitena iga tsükli 1., 2., 8., 9., 15. ja 16. päeval.
English: The European Medicines Agency decided that Kyprolis' benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Kyprolise kasulikkus on suurem kui sellega kaasnevad riskid ja lubati ravimi kasutamine ELis.
English: As for all medicines, data on the use of Kyprolis is continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Kyprolise kasutamise kohta pidevat järelevalvet.
English: Kyprolis (carfilzomib)
Estonian: Kyprolis (karfilsomiib)
English: Cancer cells have an increased need to produce and break down proteins because they multiply rapidly.
Estonian: Vähirakkudel on suurem vajadus valke toota ja lagundada, sest need rakud paljunevad kiiresti.
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Lisateave harvikravimiks nimetatud ravimi kohta on leitav: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
English: What is Kyprolis and what is it used for?
Estonian: Mis on Kyprolis ja milleks seda kasutatakse?
English: What are the risks associated with Kyprolis?
Estonian: Mis riskid Kyprolisega kaasnevad?
English: Side effects reported with Kyprolis are carefully evaluated and any necessary action taken to protect patients.
Estonian: Kyprolise kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kyprolis have been included in the summary of product characteristics and the package leaflet.
Estonian: Kyprolise ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is given to adults who have received at least one previous treatment for their cancer.
Estonian: Kyprolis on näidustatud täiskasvanutele, kes on saanud varem vähiravi vähemalt ühe ravimiga.
English: For more information about using Kyprolis, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Kyprolise kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Regarding safety, although side effects, including severe effects, were seen with treatment involving Kyprolis, these were considered acceptable and manageable.
Estonian: Kuigi ohutuse seisukohast kaasnevad Kyprolisega toimuva raviga ka kõrvalnähud, sealhulgas rasked kõrvalnähud, peeti neid vastuvõetavaks ja hallatavaks.
English: The most serious side effects include toxic effects on the heart, lungs and liver, and hypertension (high blood pressure) that can be severe.
Estonian: Kõige raskemad kõrvalnähud on näiteks südame-, kopsu- ja maksatoksilisus ning hüpertensioon (kõrge vererõhk), mis võib olla raske.
English: Other serious side effects are dyspnoea, acute kidney injury, tumour lysis syndrome (a complication due to the breakdown of cancer cells), infusion-related reactions, thrombocytopenia, internal bleeding, posterior reversible encephalopathy syndrome (a brain disorder that can cause headache, confusion, fits and loss of vision, and which may improve over time) as well as thrombotic microangiopathy and TTP/HUS (diseases involving problems with the blood clotting system).
Estonian: Muud rasked kõrvalnähud on hingamisraskused, äge neerupuudulikkus, tuumori lüüsi sündroom (vähirakkude lagunemise tõttu tekkiv tüsistus), infusioonireaktsioonid, trombotsütopeenia, sisemine verejooks, posterioorse pöörduva entsefalopaatia sündroom (ajuhäire, mis võib põhjustada peavalu, segasust, epilepsiaepisoode ja nägemiskaotust ning mis võib aja jooksul paraneda), samuti trombootiline mikroangiopaatia ja trombootiline trombotsütopeeniline purpura / hemolüütilis-ureemiline sündroom (hüübimissüsteemi teatud haigused).
English: The Agency noted the unmet medical need for patients with multiple myeloma who no longer improve with the available therapies.
Estonian: Amet märkis, et hulgimüeloomiga patsientidel, kelle haigus ei parane enam olemasolevate ravimitega, on ravivajadus täitmata.
English: The active substance in Kyprolis, carfilzomib, is a proteasome inhibitor.
Estonian: Kyprolise toimeaine karfilsomiib on proteasoomi inhibiitor.
English: Kyprolis must not be used in women who are breastfeeding.
Estonian: Kyprolist ei tohi kasutada imetamise ajal.
English: Further information on Kyprolis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Kyprolise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reportsKokkuvõtte viimane uuendus: 03.2018.
English: How is Kyprolis used?
Estonian: Kuidas Kyprolist kasutatakse?
English: Kyprolis taken together with lenalidomide and dexamethasone has been compared with lenalidomide plus dexamethasone in one main study involving 792 patients with multiple myeloma whose disease had got worse after previous treatment.
Estonian: Koos lenalidomiidi ja deksametasooniga kasutatavat Kyprolist võrreldi lenalidomiidi ja deksametasooni kombinatsiooniga ühes põhiuuringus, milles osales 792 hulgimüeloomiga patsienti, kelle haigus oli pärast varasemat ravi süvenenud.
English: Treatment may need to be stopped or the dose reduced, if the disease gets worse or the patient has severe side effects.
Estonian: Kui haigus süveneb või patsiendil tekivad rasked kõrvalnähud, võib olla vaja ravi peatada või annust vähendada.
English: The most common side effects with Kyprolis (which may affect more than 1 in 5 people) are anaemia (low red blood cell counts), tiredness, nausea, diarrhoea, thrombocytopenia (low blood platelet counts), fever, dyspnoea (difficulty breathing), respiratory tract (airways) infection, cough and neutropenia (low levels of neutrophils, a type of white blood cell).
Estonian: Kyprolise kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on aneemia (erütrotsüütide ehk vere punaliblede vähesus), väsimus, iiveldus, kõhulahtisus, trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus), palavik, raskendatud hingamine, hingamisteede infektsioon, köha ja neutropeenia (neutrofiilide ehk teatud valgeliblede vähesus).
English: What benefits of Kyprolis have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kyprolise kasulikkus?
English: The study showed that Kyprolis is effective at prolonging the time patients lived without their disease getting worse (progression-free survival): patients receiving Kyprolis with lenalidomide and dexamethasone lived on average for 26.3 months without their disease getting worse, compared with 17.6 months for patients receiving lenalidomide plus dexamethasone.
Estonian: Uuringus selgus, et Kyprolis oli efektiivne patsientide progresseerumiseta elumuse (kui kaua patsiendid elasid ilma haiguse süvenemiseta) pikendamiselKyprolist koos lenalidomiidi ja deksametasooniga kasutanud patsientide keskmine progresseerumiseta elumus oli 26,3 kuud ning lenalidomiidi koos deksametasooniga kasutanud patsientidel 17,6 kuud.
English: How does Kyprolis work?
Estonian: Kuidas Kyprolis toimib?
English: Multiple myeloma is rare, and Kyprolis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 3 June 2008.
Estonian: Hulgimüeloom esineb harva ja Kyprolis nimetati 3. juunil 2008 harvikravimiks.
English: When carfilzomib stops the proteasome from breaking down proteins in the cancer cells, the proteins build up and cause the cells to die, slowing down the growth of the cancer.
Estonian: Karfilsomiib peatab valkude lagunemise vähirakkudes, mille tõttu kogunevad valgud rakkudesse ja rakud hävivad, aeglustades vähi arengut.
English: After the first week the dose is increased if the side effects are manageable.
Estonian: Kui kõrvalnähud on hallatavad, suurendatakse annust pärast esimest nädalat.
English: Another study in 929 multiple myeloma patients whose disease had got worse after previous treatment compared the combination of Kyprolis and dexamethasone with bortezomib and dexamethasone.
Estonian: Veel ühes uuringus, kus osales 929 hulgimüeloomiga patsienti, kelle haigus oli pärast varasemat ravi süvenenud, võrreldi Kyprolise ja deksametasooni kombinatsiooni bortesomiibi ja deksametasooniga.
English: Kyprolis can only be obtained with a prescription and treatment must be supervised by a doctor experienced in the treatment of cancer.
Estonian: Ravi peab toimuma vähiravis kogenud arsti järelevalve all.
English: This means that it blocks the proteasome, which is a system within the cells that breaks down proteins that are no longer needed.
Estonian: Toimeaine blokeerib proteasoomi ehk rakusisese süsteemi, mis lagundab ebavajalikke valke.
English: It considered that the increase in time without the disease getting worse with Kyprolis was clinically meaningful.
Estonian: Ameti arvates on Kyprolise korral esinenud pikem progresseerumiseta elumus kliiniliselt oluline.
English: The study showed that the combination of Kyprolis and dexamethasone is more effective at improving progression-free survival than bortezomib and dexamethasone: patients receiving Kyprolis plus dexamethasone lived for an average of 18.7 months without their disease getting worse, compared with 9.4 months for patients receiving bortezomib and dexamethasone.
Estonian: Uuringus selgus, et Kyprolise ja deksametasooni kombinatsioon oli progresseerumiseta elumuse pikendamisel bortesomiibist ja deksametasoonist efektiivsem - Kyprolist koos deksametasooniga kasutanud patsientide keskmine progresseerumiseta elumus oli 18,7 kuud ning bortesomiibi ja deksametasooni kasutanud patsientidel 9,4 kuud.
English: Kyprolis contains the active substance carfilzomib.
Estonian: Kyprolis sisaldab toimeainena karfilsomiibi.
English: An overview of Kyprolis and why it is authorised in the EU
Estonian: Ülevaade ravimist Kyprolis ja ELis müügiloa väljastamise põhjendus
English: Kyprolis is a cancer medicine used together with the medicines lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow).
Estonian: Kyprolis on vähiravim, mida kasutatakse hulgimüeloomi (teatud luuüdivähk) raviks koos teiste ravimite lenalidomiidi ja deksametasooniga või üksnes deksametasooniga.
English: From cycle 13 onwards, the doses on day 8 and 9 are omitted if Kyprolis is used with lenalidomide and dexamethasone.
Estonian: Kui Kyprolist kasutatakse koos lenalidomiidi ja deksametasooniga, jäetakse alates 13. tsüklist 8. ja 9. päeva annused ära.
English: Kyprolis is available as a powder to be made up into a solution for infusion (drip) into a vein.
Estonian: Kyprolist turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: Boulevard de la Plaine 17 1050 Brussels Belgium200 mg/100ml Solution for Infusion
Estonian: Boulevard de la Plaine 17 1050 Brussels Belgium200 mg/100ml Infusioonilahus Intravenoosne
English: Solution for Intravenous Infusion
Estonian: Intravenoosne infusioonilahus
English: CT13 9NJ United Kingdom200 mg/100ml Solution for Infusion
Estonian: CT13 9NJ United Kingdom200 mg/100ml Infusioonilahus Intravenoosne
English: Powder for Suspension
Estonian: Suspensiooni pulber
English: s r.o., Stroupežnického 17
Estonian: s r.o., Stroupežnického 17 150 00 Prague 5
English: 400 mg/200ml Solution for Infusion
Estonian: 400 mg/200ml Infusioonilahus Intravenoosne
English: 200 mg/100ml Solution for Infusion
Estonian: 200 mg/100ml Infusioonilahus Intravenoosne
English: Diflucan i.v.-400mg 400 mg/200ml Solution for Infusion
Estonian: Diflucan i.v.-400mg 400 mg/200ml Infusioonilahus Intravenoosne
English: Diflucan i.v.-200mg 200 mg/100ml Solution for Infusion
Estonian: Diflucan i.v.-200mg 200 mg/100ml Infusioonilahus Intravenoosne
English: Infusion
Estonian: Intravenoosne
English: This summary was last updated in 07-2012.
Estonian: Kokkuvõtte viimane uuendus: 07.2012.
English: In these two studies, patients were treated for four weeks.
Estonian: Mõlemas uuringus raviti patsiente 4 nädalat.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cayston on 21 September 2009.
Estonian: Euroopa Komisjon andis Caystoni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. septembril 2009.
English: The additional study produced results that were consistent with those of the main studies.
Estonian: Lisauuringu tulemused olid kooskõlas põhiuuringute tulemustega.
English: The CHMP decided that Cayston's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Caystoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
English: This document is a summary of the European public assessment report (EPAR) for Cayston.
Estonian: Käesolev dokument on ravimi Cayston Euroopa avaliku hindamisaruande kokkuvõte.
English: EPAR summary for the public aztreonam
Estonian: Kokkuvõte üldsusele astreonaam
English: A third main study involving 268 patients (including 59 children from six to 17 years of age) compared Cayston with another inhaled antibiotic (tobramycin nebuliser solution).
Estonian: Kolmas põhiuuring, milles osales 268 patsienti (sh 59 last vanuses 6-17 aastat), võrdles Caystonit teise inhaleeritava antibiootikumiga (tobramütsiini nebulisatsioonilahus).
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Cayston can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Caystoni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The full EPAR for Cayston can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Caystoni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: An improvement in lung function was also seen in children aged six to 17 years, both after four weeks of treatment and after three treatment cycles.
Estonian: Kopsutalitlus paranes ka 6-17-aastastel lastel nii 4-nädalase ravi kui ka kolme ravitsükli järel.
English: Cayston is given three times a day for four weeks, with at least four hours between each dose.
Estonian: Caystonit manustatakse kolm korda ööpäevas neli nädalat järjest, manustades iga annuse vähemalt neli tundi pärast eelmist.
English: The third study showed that Cayston compared favourably with the comparator antibiotic: after four weeks of treatment, the increase in FEV1 adjusted for age, height and sex was 8.35% with Cayston and 0.55% with the comparator; after three treatment cycles, the increase with Cayston was 2.05% compared with a decrease of 0.66% with the comparator.
Estonian: Kolmas uuring näitas, et Caystoniga saavutati parem tulemus kui võrdlusantibiootikumiga: 4-nädalase ravi järel suurenes vanuse, kasvu ja soo järgi kohandatud FEV1 Caystoni korral 8,35% ja võrdlusravimi korral 0,55%; kolme ravitsükli järel suurenes FEV1 Caystoni korral 2,05%, võrdlusravimi korral aga vähenes 0,66%.
English: What is Cayston?
Estonian: Mis on Cayston?
English: The most common side effects with Cayston (seen in more than 1 patient in 10) are wheezing, cough, pharyngolaryngeal pain (pain in the throat and voice box), nasal congestion (blocked nose), dyspnoea (difficulty breathing) and fever.
Estonian: Caystoni kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on vilisev hingamine, köha, neelu ja kõri valulikkus, ninakinnisus, düspnoe (õhupuudustunne) ja palavik.
English: For more information about treatment with Cayston, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Caystoniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Cayston:
Estonian: Muu teave Caystoni kohta
English: Cayston is to be used with a nebuliser (a special machine that changes the solution into an aerosol that the patient can breathe in).
Estonian: Caystonit tuleb manustada nebulisaatoriga (spetsiaalne seade, mis muudab lahuse aerosooliks, mida patsient saab sisse hingata).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cayston.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The CHMP concluded that there was an unmet medical need for new antibiotics in patients with cystic fibrosis, since many of these patients have already developed resistance to other antibiotics by the time they reach adulthood, and because P. aeruginosa lung infections are a cause of severe health problems in patients with cystic fibrosis.
Estonian: Inimravimite komitee järeldas, et tsüstilise fibroosiga patsientide raviks on vaja uusi antibiootikume, sest paljud patsientidest on täiskasvanuks saades muutunud teiste antibiootikumide suhtes resistentseks ja P. aeruginosa põhjustatud kopsuinfektsioonid tekitavad tsüstilise fibroosiga patsientidel raskeid terviseprobleeme.
English: The main measure of effectiveness was based on improvements in patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).
Estonian: Efektiivsuse põhinäitaja aluseks oli patsiendi forsseeritud ekspiratoorse mahu (FEV1, maksimaalne õhu maht, mille patsient hingab sekundis välja) suurenemine.
English: This leads to problems with the digestion and absorption of food, resulting in poor growth, and long-term infection and inflammation of the lungs because of excess mucus not being cleared away.
Estonian: See põhjustab toidu seedimisel ja imendumisel häireid, mille tagajärjel kasv pidurdub, ning pikaajalist kopsuinfektsiooni ja kopsukelmepõletikku, sest liigset lima ei eemaldata.
English: In the first study, the main measure of effectiveness was how long it took before the patients needed other antibiotics by inhalation or injection into a vein.
Estonian: Esimeses uuringus oli efektiivsuse põhinäitaja aeg, mis kulus selleni, kuni patsiendid vajasid muid sissehingatavaid või intravenoosseid antibiootikume.
English: Because the number of patients with bacterial lung infection in cystic fibrosis is low, the disease is considered ‘rare', and Cayston was designated an ‘orphan medicine' (a medicine used in rare diseases) on 21 June 2004.
Estonian: Et bakteriaalse kopsuinfektsiooniga tsüstilise fibroosiga patsientide arv on väike ja see haigus esineb harva, nimetati Cayston 21. juunil 2004 harvikravimiks.
English: It works by attaching to proteins on the surface of the P. aeruginosa bacteria.
Estonian: Toimeaine seondub valkudega bakteri P. aeruginosa pinnal.
English: Why has Cayston been approved?
Estonian: Miks Cayston heaks kiideti?
English: In the first study, the patients who received Cayston required other antibiotics after 92 days, compared with 71 days for the patients who received placebo.
Estonian: Esimeses uuringus vajasid Caystonit võtnud patsiendid muid antibiootikume pärast 92 päeva ja platseebot võtnud patsiendid pärast 71 päeva.
English: In Cayston, aztreonam is available as a ‘lysine salt', which makes it possible for the antibiotic to be breathed directly into the lungs without causing irritation.
Estonian: Cayston sisaldab astreonaami lüsiinsoolana, mis võimaldab antibiootikumi hingata otse kopsu, ilma et see põhjustaks ärritust.
English: Aztreonam has been available as an injection since the 1980s as an ‘arginine salt'.
Estonian: Astreonaami on arginiinsoola süstina manustatud alates 1980. aastatest.
English: Cayston must not be used in people who are hypersensitive (allergic) to aztreonam or any of the other ingredients.
Estonian: Caystonit ei tohi kasutada patsiendid, kes on astreonaami või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Cayston is a powder and solvent that are made up into a nebuliser solution.
Estonian: Cayston on pulber ja lahusti, millest valmistatakse nebuliseeritav lahus.
English: Cayston was compared with placebo (a dummy treatment) in two main studies involving a total of 375 patients with cystic fibrosis who had long-term lung infection due to P.aeruginosa, most of whom were adults.
Estonian: Caystonit võrreldi platseeboga (näiv ravim) kahes põhiuuringus, milles osales 375 tsüstilise fibroosiga patsienti, kellel oli pikaajaline P.aeruginosa põhjustatud kopsunakkus; enamik patsiente olid täiskasvanud.
English: What is the risk associated with Cayston?
Estonian: Mis riskid Caystoniga kaasnevad?
English: In patients with cystic fibrosis, P. aeruginosa infections usually start in the first 10 years of life and can cause long-term lung problems.
Estonian: Tsüstilise fibroosiga patsientidel algavad bakteri P. aeruginosa põhjustatud infektsioonid esimesel 10 eluaastal ja võivad põhjustada kroonilisi kopsuprobleeme.
English: For the full list of all side effects reported with Cayston, see the package leaflet.
Estonian: Caystoni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In the second study, the main measure of effectiveness was how the patients rated their respiratory symptoms on a standard scale for cystic fibrosis.
Estonian: Teises uuringus oli efektiivsuse põhinäitaja hinnang, mille patsiendid andsid oma hingamiselundite sümptomitele tsüstilise fibroosi standardskaalal.
English: In cystic fibrosis, the patient's lungs produce too much thick mucus, which allows bacteria to grow more easily.
Estonian: Tsüstilise fibroosi korral tekib patsiendi kopsudes liiga palju paksu lima, mis soodustab bakterite arenemist.
English: If the doctor thinks that further treatment cycles with Cayston are needed after the first course, a gap of four weeks is recommended after every four-week treatment cycle with Cayston.
Estonian: Kui arst peab pärast esimest kuuri vajalikuks Caystoni ravi jätkamist, on soovitatav teha enne järgmist neljanädalast Caystoni ravikuuri vähemalt neljanädalane vaheaeg.
English: The active substance in Cayston, aztreonam, is an antibiotic that belongs to the group ‘beta-lactams'.
Estonian: Caystoni toimeaine astreonaam on beetalaktaamide gruppi kuuluv antibiootikum.